leisure time -WSS

leisure time

author：knowledge 2025-09-27 09:55:07 - browse：793

Two researchers look at a projection screen displaying medical devices, scientific graphs and DNA — health tech coverage from STAT — Adobe

The federal government’s plan to boost its oversight of the use of artificial intelligence tools in health care drew censure from startups arguing that overregulation stifles new ideas. But as Washington forges ahead, founders say they’re in the dark about who will be regulated and how — and they’re urging policymakers to offer clarity.

As they race for a slice of the $4 trillion U.S. health care market, AI founders and investors say regulatory uncertainty is a hurdle, forcing them to build more slowly and meticulously document for fear of potential audits. That makes it harder to keep up with the tech industry’s breakneck pace, they tell STAT.

The regulatory uncertainty adds to the many challenges dogging young health tech ventures today: Last year investments in digital health startups shriveled to their lowest annual total since 2019, and leaders are desperate to preserve what little funds they have, including through layoffs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Brain technologies pose threats that are all too real, experts warn

WSS

Congress may force more Covid

HHS's proposed rule does nothing to address the climate crisis

As billionaires fund anti

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Novel spinal cord stimulator treats paralysis without surgery

Weight loss drugs aren’t covered by Obamacare. That may change

hotspot

leisure time

focus

Jerome Adams on the need for new antivirals for Covid

Flagship Pioneering startup Sonata Therapeutics lays off 21

New air purifier tech could be key to improving indoor air quality

Surprise medical billing ban raises prices elsewhere

United colonoscopy coverage change 'may cost lives,' doctors say

AltruBio raises $225 million to develop ulcerative colitis drug

Jerome Adams on the need for new antivirals for Covid

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

DIEP, the 'gold standard' of breast reconstruction, is under threat

As billionaires fund anti

leisure time

Weight loss drugs aren’t covered by Obamacare. That may change

Brain MRIs reveal impact of 'toxic stress' on Black children

AltruBio raises $225 million to develop ulcerative colitis drug

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

New study raises questions about niacin and heart health

Welsh Carson private equity firm escapes from FTC antitrust case

hotspot

knowledge

hotspot

leisure time